MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
Turning Point Therapeutics Revenue 2011-2026 | TPTX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Turning Point Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 30.8 M | 25 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.8 M | 25 M | 27.9 M |
Quarterly Revenue Turning Point Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 119 K | 429 K | - | 460 K | 5.16 M | 25.2 M | - | 25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25.2 M | 119 K | 9.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
2.19 M | $ 8.79 | 0.8 % | $ 86.9 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.6 | -1.64 % | $ 8.66 B |  Australia |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Applied Therapeutics
APLT
|
9.99 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
BioNTech SE
BNTX
|
482 M | $ 97.22 | 0.54 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
330 M | $ 4.64 | 3.45 % | $ 754 M | Britain |
 |
Cabaletta Bio
CABA
|
0.006 | $ 3.21 | 0.16 % | $ 323 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 21.3 | -0.3 % | $ 996 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
41 K | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
8.23 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
236 M | $ 1.51 | 2.59 % | $ 388 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 3.15 | 7.87 % | $ 5.19 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
44.5 M | $ 4.2 | 0.24 % | $ 449 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 25.08 | 3.96 % | $ 3.19 B | USA |
 |
Chimerix
CMRX
|
324 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
7.9 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Evogene Ltd.
EVGN
|
3.85 M | $ 0.82 | -0.07 % | $ 27.9 M | Israel |
 |
Celldex Therapeutics
CLDX
|
1.54 M | $ 32.73 | 0.43 % | $ 2.17 B | USA |
 |
Forte Biosciences
FBRX
|
18 M | $ 32.72 | 6.91 % | $ 424 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.49 | 1.27 % | $ 397 M | Britain |
 |
Cidara Therapeutics
CDTX
|
1.28 M | - | - | $ 1.41 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
58.7 B | - | - | $ 96.9 B | Britain |